Pure Global
NCT06221670

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

Efficacy and Safety of Toripalimab Adjuvant Therapy in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) After Complete Resection: a Prospective, Single-arm Study
Tianjin Medical University Cancer Institute and Hospital·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
Toripalimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tianjin Medical University Cancer Institute and Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Mar 20, 2024
End date
Mar 20, 2031
Enrollment
51 participants
Primary outcome

3-year DFS rate

Summary

This is a prospective, open, single-center, single-arm phase II clinical study in non-small
 cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK
 fusion variants identified in the central laboratory. To evaluate the efficacy and safety of
 adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with
 high-risk factors.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06221670
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06221670 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on NSCLC. Target enrollment is 51 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.